Form 4 Filing for Regeneron Pharmaceuticals, Inc. - Officer/Director Transaction

Arthur F. Ryan, a director at Regeneron Pharmaceuticals, Inc. (REGN), reported a sale of 200 shares of common stock on July 2, 2026. The transaction, executed under a Rule 10b5-1(c) plan, resulted in a sale price of $650.15 per share. This sale was part of a volume-weighted average price of sales ranging from $650.10 to $650.19. Following this transaction, Ryan holds 17,303 shares of Regeneron stock. The filing was made on July 7, 2026. Ryan is not an officer but is a director at the company.